The companies entered into a three-year collaboration agreement in January 2024, granting AstraZeneca exclusive rights to use Omniose’s bioconjugation platform. This is a method for biologically linking different components of a conjugate vaccine to generate a stronger immune response.
Omniose’s technology differs from traditional conjugate vaccine manufacturing in that the components are linked inside a genetically modified bacterial cell, rather than through a separate chemical process.
BREAKING